Introduction
Fatigue is one of the most common symptoms of multiple sclerosis (MS), 1e3 a chronic autoimmune disorder of the central nervous system. 4 Often described as a feeling of extreme mental or physical exhaustion, MS-related fatigue has far-reaching effects on quality of life, employment, and productivity, 5e7 imposing limitations independently of MS-related physical disability and depression.
measurement properties suggests shortcomings in terms of current standards for PRO instrument development. For instance, the 9-item Fatigue Severity Scale (FSS) and the 21-item Modified Fatigue Impact Scale (MFIS) do not fit the assumption of unidimensionality, and so studies using their global scores may need to be reevaluated. 21, 22 A primary requirement is to develop and validate a PRO instrument in the disease-specific target patient population for intended use. The clinical course of MS broadly falls into relapsing and progressive forms (RMS and PMS, respectively). 23 Three RMS subtypes are recognized. 23e25 Relapsing-remitting MS (RRMS), seen in approximately 80% to 85% of MS patients, is characterized by acute exacerbations with full or partial recovery, and patients are generally stable between exacerbations. Progressive-relapsing MS (PRMS), which afflicts roughly 5% of MS patients, is marked by progression starting at disease onset, with occasional relapses. Relapsing secondary-progressive MS (RSPMS) gradually progresses later (after a median of 20 years) in the disease course of approximately 65% to 70% of RRMS patients.
As symptoms and their impacts could differ among these various forms of MS, a PRO instrument should be validated in the specific MS subtypes for which it will be used. A unidimensional version of the FIS (U-FIS) has been developed to address the multidimensionality of the original 40-item Fatigue Impact Scale (FIS) and the MFIS, 17, 26 but some participants in its validation research were recruited from patient organizations rather than clinical centers, precluding confirmation of all participants' MS diagnoses or their type of MS. Some other MS-specific fatigue questionnaires, such as the FSS, 15 were developed in patients with PMS rather than RMS, which may affect their applicability as outcome measures in RMS.
Another issue is whether a questionnaire comprehensively measures MS symptoms and their impact; for example, the FSS does not include items regarding cognitive fatigue, 27 whereas the FIS and MFIS assess the impact of symptoms on patient functioning, rather than measuring the severity of the symptoms themselves. 2, 10, 16 The objective of the present research was to address limitations of existing MS-specific instruments by developing a new, content-valid, concise PRO instrument to assess fatigue symptoms relevant to patients within the spectrum of RMS and the relevant impact of these symptoms on patients' lives, in accordance with the FDA PRO guidance.
Methods

Overview
Development and psychometric validation of the new PRO instrument was conducted in 6 research stages, preceded by a literature review (Fig. 1) . Development of the draft questionnaire was based on qualitative research in patients with RMS, including concept elicitation and cognitive interviews (n ¼ 17 and 20, respectively) in patients with RRMS, and content confirmation interviews in patients with PRMS (n ¼ 5) and RSPMS (n ¼ 5). Finalization of the new instrument and psychometric validation analyses were based on data gathered in an observational study, a real-world cross-sectional study, and a study to confirm the conceptual equivalence and usability of an electronic version of the questionnaire.
All study-stage protocols were approved by centralized Institutional Review Boards, and all participants provided written informed consent. All interviews were conducted by experienced interviewers trained in the use of semistructured interview guides specific to each study stage.
Literature Review
Literature reviews were conducted to identify evidence on fatiguerelated symptoms of RMS and their impacts. Relevant data were used to inform development of preliminary conceptual frameworks for RMS symptoms and impacts, which in turn were used to inform the concept elicitation interview guides. Searches were conducted in Medline and covered a 10-year period for RRMSrelated searches (January 2000 to September 2010) and for subsequent searches pertaining to PRMS and RSPMS (January 2002 to February 2012).
Qualitative Research
Stage 1: concept elicitation interviews in RRMS
Face-to-face concept elicitation interviews in patients with RRMS were conducted to identify and describe fatigue-related symptoms and impacts from the patient perspective. The FIS was also cognitively debriefed to determine the extent to which it may assess RRMS symptoms and impacts and therefore be fit for purpose as an efficacy endpoint measure.
In these concept elicitation interviews, each participant was asked open-ended questions to spontaneously elicit fatiguerelated symptoms of RRMS and their impacts as experienced by the participant. Probing questions were posed if the initial openended queries did not elicit an explicit description of a fatiguerelated symptom or impact.
After qualitative analysis of the interview transcripts, concept saturation was assessed. Saturation was considered to be achieved at the point at which no new, relevant concepts emerged from subsequent interviews. A sample size of 15 was anticipated to be sufficient to achieve saturation. 28 Two additional participants were recruited to account for no-shows or cancellations.
As described in the Results, the FIS would have required too many modifications to attain content validity in an RRMS population. Therefore, a new PRO instrument to assess fatigue-related symptoms of RRMS and their impacts was drafted by the investigators based on the concepts spontaneously elicited in interviews. After the preliminary conceptual framework, the instrument comprised a symptoms domain with a 24-hour recall period and an impacts domain with a 7-day recall period. Concepts reported by more than 5 (>29.4%) of the 17 participants were selected for inclusion in the initial paper questionnaire. The new instrument was named the "Fatigue Symptoms and Impacts QuestionnairedRelapsing Remitting Multiple Sclerosis" (FSIQ-RRMS).
Stage 2: cognitive interviews in RRMS
Face-to-face cognitive interviews were conducted to assess the relevance, comprehensibility, acceptability, and comprehensiveness of its items, in addition to the interpretability and appropriateness of instructions, response options, and the recall period of the FSIQ-RRMS. These cognitive interviews included 20 patients with RRMS who had not been included in stage 1.
An item was subject to revision if at least 5 (!25.0%) of the 20 respondents gave consistent recommendations for its change (eg, rewording or deletion), demonstrated difficulty interpreting it, or did not interpret it as intended. The same threshold was applied for the addition of suggested new items to the questionnaire.
Stage 3: content confirmation interviews in PRMS and RSPMS
After stage 2, it was decided to expand the target population for the new PRO instrument to encompass a broader range of RMS patients. One-on-one content confirmation interviews were conducted in patients with PRMS or RSPMS to test the understandability, comprehensiveness, and relevance of the instrument in these RMS subtypes.
Concept elicitation and cognitive interviews were conducted using semistructured interview guides based on preliminary conceptual frameworks developed for RSPMS and PRMS fatiguerelated symptoms and impacts. Interview findings indicated that no revisions were required for application of the PRO instrument to patients with PRMS and RSPMS. The instrument was renamed the "Fatigue Symptoms and Impacts QuestionnairedRelapsing Multiple Sclerosis" (FSIQ-RMS).
Psychometric Validation
Stage 4: observational study
Psychometric validation was performed in an observational study that also included a control group of non-MS patients to demonstrate the ability of RMS patients to attribute fatigue symptoms to their disease (n ¼ 164 patients with RMS þ 74 controls).
Psychometric analyses included tests of item response and dimensionality, Rasch and exploratory factor analyses to assess content validity, and analyses of construct validity, internal consistency reliability, and testeretest reliability. These analyses were followed by an attribution analysis and development of a scoring algorithm. After item reduction, the final version of the questionnaire underwent confirmatory factor analysis, Rasch analysis (only conducted on the unidimensional domain; ie, symptoms), known-groups analysis (only for the symptoms domain because the focus of the instrument was to be able to support a PRO labeling claim for symptoms), and assessments of concurrent and discriminant validity and of internal consistency and testeretest reliability (for symptoms and impacts domains).
In the 12-week study period, patients with RMS were instructed to complete the paper version of the FSIQ-RMS at home (apart from day 1) during 2 intervals: interval 1, from days 1 to 8, where day 1 was used to collect baseline data on the symptoms and impacts items, whereas days 2 to 8 were the first full week of completion of the instrument, and interval 2, from days 80 to 86. Participants were instructed to complete the symptoms domain daily and the impacts domain on days 1, 8, and 86.
Additional PRO questionnaires had to be completed at 3 site visits. Visit 1 occurred on day 1, whereas visits 2 and 3 could occur within a 3-day window after completion of intervals 1 and 2 to accommodate participants' scheduling conflicts. Additional instruments administered included the Medical Outcomes Study RAND-36 29 at visits 1 and 3, and Patient Global Impression of Severity (PGI-S) scales 30 modified for RMS and fatigue and the MFIS 10 at visits 1, 2, and 3. Clinicians completed the Expanded Disability Status Scale (EDSS) 31 at visit 1, and a Clinician Global Impression of Change (CGI-C) 32 at visits 2 and 3.
Control participants without an MS diagnosis completed an adaption of the FSIQ-RMS with all references to RMS removed, at home from days 1 to 7 with a site visit at day 1. Control participants were patients presenting for an acute condition or a checkup and were required to meet the eligibility criteria described in Table 1 . Controls were individually matched to RMS patients by sex, age group (in 10-year age cohorts), and race or ethnicity. 
addition to a real-world study conducted in Germany and the United States, the FSIQ-RMS was administered to provide data for a supplementary analysis of performance of the symptom items in a real-world setting (n ¼ 154), and to assess differential item functioning in MS patients with depression. As the real-world study was not designed specifically to validate the FSIQ-RMS, it is reported only briefly here, with further details provided in Appendix 1 (see Supplemental Materials found at https://doi.org/1 0.1016/j.jval.2018.11.007).
Stage 6: eDiary migration and usability study
The final stage was a qualitative migration and usability study in patients with RMS in the United States (n ¼ 10) to demonstrate readability, ease of use, acceptability of an electronic version of the FSIQ-RMS ("eDiary"), and conceptual equivalence between paper and electronic platforms (stage 6).
Before testing, minor changes were made to the FSIQ-RMS to simplify the instructions (these changes were also made to the 
paper version), with additional changes to make them appropriate for administration on a handheld electronic devicedspecifically, a BLU Life Play Android smartphone. The eDiary presented the questionnaire in landscape format with 1 item per screen, providing more room for the horizontal numeric rating scale and space between the responses to facilitate response selection for MS patients who may have problems with fine motor control. At in-person site visits, participants received training on use of the eDiary, and completed paper and eDiary versions of the FSIQ-RMS and a device-usability questionnaire with 6 questions scored on a verbal rating scale anchored at 1 ("Very easy") and 5 ("Very difficult").
One-on-one cognitive interviews were conducted to probe for participants' interpretation of questions and response options and their perspectives on the usability of the eDiary.
Patient Population
Other than the control participants, all participants in all study stages had RMS diagnoses as defined by the revised McDonald Diagnostic Criteria for MS, 34 with additional subtype diagnostic criteria for the RRMS, PRMS, and RSPMS patients. Recruitment aimed to enroll participants generally representative of the RMS population likely to be enrolled in future clinical trials.
As shown in Table 1 , eligibility criteria were highly consistent across study stages. Nevertheless, the upper limit of the age range for eligibility was decreased from 65 years in early study stages to 55 years in later stages to align with the inclusion criteria in 2 phase 3 trials of ponesimod in RMS (OPTIMUM ClinicalTrials.gov identifier NCT02425644 and POINT ClinicalTrials.gov identifier NCT02907177).
Data Analysis
For the qualitative research, participant interviews were audio recorded, transcribed, and anonymized by a third-party transcription agency for qualitative analysis using ATLAS.ti software (ATLAS.ti Scientific Software Development GmbH, Berlin, Germany). Initial coding schemes were developed based on the respective interview guides. Codes were reviewed and modified by the coders as transcripts were analyzed.
In the psychometric validation analyses, item scores were assessed for floor and ceiling effects (ie, the clustering of item scores at the top and bottom of the response-scale range, respectively); a threshold of !9% of respondents in the highest or lowest response option was applied. Item discrimination was evaluated using the proportion of participants who endorsed a score for each symptom item within the range of their overall score severity across items (categorized as mild ¼ 0 to 3, moderate ¼ 4 to 6, or severe ¼ 7 to 10), with a threshold of 50%. For inter-item correlation analysis, item pairs with polychoric correlation coefficients of >0.8 were considered to have a high correlation. 35 Because the symptoms domain was considered to measure a unidimensional construct, only symptom items with inter-item correlations greater than 0.90 were reviewed for potential deletion. In exploratory factor analysis, items with factor loadings <0.40 on all factors identified were reviewed for possible deletion. 36 Internal consistency reliability was assessed by calculating the Cronbach's alpha coefficient for each domain and was considered to be met if the Cronbach's alpha coefficient was >0.70. 37 Evaluation of the item hierarchy and ability of the instrument to distinguish between high and low performers used item and person separation indices and item and person reliability indices, with acceptance thresholds of >2.0 for separation indices and >0.8 for reliability indices. 38 Testeretest reliability was assessed using the intraclass correlation coefficient (ICC), calculated using ShrouteFleiss reliability for a single score, with an ICC of !0.70 considered to be acceptable. 39 Unidimensionality was considered to have been demonstrated if >60% of variance was explained by the Rasch factor and <5% was explained by the first residual factor. 40 
Results
Participant Characteristics
Characteristics of the participants are reported in Table 2 . Across the study stages, participants were predominantly female with mild-to-moderate disease severity, and diverse in age, race/ ethnicity, work status (see Appendix 2 in the Supplemental Materials found at https://doi.org/10.1016/j.jval.2018.11.007 for additional employment details), and educational attainment.
Stage 1: Concept Elicitation Interviews in RRMS
Concept elicitation interviews were conducted with a total of 17 participants at 3 US sites in November 2010, and analyses demonstrated that saturation was achieved.
The most commonly reported fatigue-related symptoms were energy and weakness. Functional and emotional impacts of fatigue-related symptoms were reported, including difficulty walking, maintaining relationships, participating in social activities, and performing general activities of daily living, as well as difficulty with thought processes. Elicited symptom and impact concepts are reported in Table 3 .
Based on the cognitive debriefing of the FIS, it was determined that this instrument does not sufficiently measure fatigue-related symptoms and their impacts on the RRMS population. The FIS is primarily an impact instrument. Furthermore, most concepts represented in the FIS were reported infrequently or not at all by participants; conversely, several concepts elicited were not present in the FIS.
Based on the results of the concept elicitation interviews and applying the above-mentioned criteria to generate items, a draft version of the new PRO instrument was developed. Instrument drafting also took into account evidence from the literature review and input from clinical experts experienced in treating patients with MS. Reasons for including or not including elicited concepts in the draft instrument are presented in Table 3 . Named the "FSIQ-RRMS," the questionnaire comprised 30 items across 2 hypothesized domains: fatigue-related symptoms (n ¼ 16) and impacts of fatigue-related symptoms (n ¼ 14).
Symptom items use an 11-point numeric rating scale assessing the severity of each item, with response options ranging from "Not at all" (0) to "Extremely" (10). This response scale was selected as it is commonly used in clinical settings to assess symptom severity. A recall period of "the past 24 hours" was chosen because symptoms may vary between days.
Impact items use a 5-point verbal rating scale to assess the severity or frequency of each impact, with response options ranging from "No difficulty" to "Extreme difficulty," "Not at all" to "Extremely," or "Never" to "Almost all of the time." A numeric rating scale was not considered appropriate for impacts because items in the impact domain of the questionnaire assess different
aspects of the patient experience (eg, severity and frequency), and so including verbal prompts for each response choice in the rating scale was considered to be important. A 5-point scale was selected to allow sensitivity in the response choices without adding too much complexity for the patients. 43 A recall period of "past 7 days" was used for all impact items because impacts may not be experienced during each day of a 1-week evaluation period.
Stage 2: Cognitive Interviews in RRMS
Cognitive interviews were conducted with an additional 20 RRMS patients at 3 US sites in February 2011. Overall, the participants reported the draft FSIQ-RRMS instrument to be comprehensive, understandable, and relevant. Nevertheless, participants had a few comments, which were addressed by modifications to the draft questionnairednamely, removal of 8 symptom items that participants did not interpret as intended (all 6 "at rest" items, which were commonly misinterpreted, and both "exhausted" items, as "exhausted" overlapped with other concepts and was considered by most participants to be a more severe sensation of "tiredness"), revision of the item stem for 6 symptom items to specify that the fatigue symptoms were attributable to RRMS, revision of the item stem for all impact items to specify that the impacts experienced were attributable to fatigue, and rewording of 2 impact items to be All 5 participants referred to having to plan their day around the severity of their symptoms. Participants mentioned having to "manage" (n ¼ 1), "negotiate" (n ¼ 1), and "rearrange" (n ¼ 1) plans. "Rearrange" was selected as it was a specific impact related to planning, that would also cover the other terms. While the majority of participants referred to difficulty with their thought "process" or "processing" information (n ¼ 4), "thinking clearly" (n ¼ 1) along with other concepts were reported; "thinking clearly" was selected to simplify the item while making the concept more specific. 
more specific. No revisions were required to the recall period or response options. After revision, the PRO instrument comprised 22 items: 8 fatigue-related symptoms and 14 impacts. Subsequently, a Rasch analysis was conducted on the participant responses collected during the stage 2 cognitive interviews. Based on this analysis, a previously deleted symptom item was added back to the instrument to ensure that symptoms relevant for the severe spectrum of the disease were adequately covered, resulting in 23 items in total.
Stage 3: Content Confirmation Interviews in PRMS, RSPMS
A total of 10 patients with PRMS (n ¼ 5) or RSPMS (n ¼ 5) were interviewed at 2 US sites in May 2012. In the concept elicitation portion, new concepts were reported by only 1 or 2 participants, overlapped with already-included concepts, or were too nonspecific for inclusion in the questionnaire (eg, unable to do anything/ function physically, being in a "bad mood"). Consequently, no items were added (nor were any other modifications made) to the draft 23-item questionnaire, which was renamed the "FSIQ-RMS v1."
Stage 4: Psychometric Validation in Observational Study
Results of the psychometric analyses are summarized in Table 4 . In total, data were analyzed for 164 patients with RMS recruited from 15 US sites and 74 controls recruited from 3 US sites, between September 2012 and October 2013.
Instrument completion
Only 3 participants had 1 or more missing responses on symptom items by day 8, and no symptom item had data missing from more than 1 participant, indicating that missing data are a random effect. The FSIQ-RMS impact items also had low levels of missing data.
Item performance analysis
Participants used the full range of the symptoms scale (0 to 10) and the impacts scale (0 to 4), with similar distributions for all items. Substantial ceiling effects were observed for most symptom and impact items, reflecting the mild-to-moderate patient population with few ambulatory limitations. Symptom items without ceiling effects on day 1 and/or day 8 were "Physically tired," "Physically fatigued," and "Energy doing routine daily activities." The only impact item without ceiling effects on visit 2 (day 9 to 11) was, "How often did you have to take a break?" High pairwise inter-item correlations (!0.94) on days 1 and 8, potentially indicating redundancy between content-related item pairs, were observed for the symptom items "Mentally tired" and "Mentally fatigued" and for "Physically tired" and "Physically fatigued." No impact item pairs had correlations >0.8 on both days 1 and 8.
The proportion of participants who endorsed a score for each symptom item within the range of their overall score severity across items was consistently above the 50% threshold, indicating that the instrument is able to discriminate between mild, moderate, and severe fatigue.
Factor analysis
In exploratory factor analysis of the 9-item symptoms domain, 1 factor explained 93.4% of the variance (Eigenvalue ¼ 47.74; P < .0001), supporting the hypothesis that the symptom items reflect a single underlying construct. Exploratory factor analysis of the 14-item impacts domain resulted in 3 factors explaining 9.68%, 8.37%, and 4.94% of the variance, respectively 
(Eigenvalue ¼ 19.92, 1.88, and 1.18, respectively; P < .0001), suggesting that the impact items can be categorized into 3 conceptual subdomains.
Rasch analysis of the 9-item symptoms domain revealed that a unidimensional factor explaining most of the variance was "fatigue." Rasch analysis of the 14-item impacts domain provided evidence of multidimensionality, with the Rasch dimension explaining 59.4% and 58.4% of the variance on days 1 and 8, respectively, thus not reaching the threshold for demonstrating unidimensionality.
Item reduction
Based on the observed redundancy between symptom items measuring "fatigue" and "tired," the items "Physically fatigued" and "Mentally fatigued" were deleted.
The impacts item related to showering was deleted because it had a substantial ceiling effect, with 57.9% of participants responding that they had no difficulty showering. There was also categorical disordering within the scale, indicating that patients do not use the response options as intended. In addition, this item may not be generally applicable in a multinational study because showers may not be available in all countries.
As a result of these modifications, the final FSIQ-RMS v2 incorporated 1 hypothesized fatigue-related symptoms domain comprising 7 items, and 3 hypothesized impacts subdomainsdphysical, cognitive/emotional, and coping (which is combined with 2 physical impacts subdomain items)dcomprising 13 items (Fig. 2) .
Scoring algorithm
A scoring algorithm was developed to standardize scores on both the symptoms domain (daily and weekly) and impacts subdomains (weekly) to a 0 to 100 scale, with higher scores indicating more severe symptoms and impacts. There is no single summary score across the FSIQ-RMS instrument, but rather 1 symptoms score and 3 impacts subdomain scores.
For the average weekly symptoms domain score to be computed, data from at least 4 daily diaries with at least 4 items (ie, !50% nonmissing item responses) completed on each day are needed. If fewer than 4 items are reported on a day, the day is considered missing. If fewer than 4 days are available within the 7-day period, the observation for the weekly average score is considered missing.
For the impacts domain, the 2 items present in both the physical and coping subdomains ("taking part in social activities" and "rearranging plans") are multidimensional, and represent coping strategies related to the physical impact of the disease. For each impacts subdomain, at least 3 items (ie, !50% nonmissing item responses) are needed to calculate the respective weekly subdomain score. If fewer than 3 items are reported, the observation for that week is considered missing.
Psychometric testing of final FSIQ-RMS
In confirmatory factor and Rasch analyses, the final FSIQ-RMS 7-item symptoms domain demonstrated unidimensionality, with the model explaining 75.0% of the variance on day 1 and 83.2% on day 8. The symptoms domain was shown to contain independent, reliable items, with item reliability indices ranging from 0.92 to 0.95 across items, exceeding the threshold for demonstrating score repeatability. Item scores were able to discriminate patients along the severity continuum, with item separation indices ranging from 3.49 to 4.35, exceeding the threshold for demonstrating sensitivity of the instrument.
In analyses of concurrent validity, a higher FSIQ-RMS symptoms score wasdas expecteddassociated with lower perceived health as measured by the RAND-36 Energy/fatigue scale on day 1, and higher fatigue symptoms as measured by the MFIS Physical subscale on days 1 and 2 to 8 ( Table 4 ). All 3 impacts subdomains were significantly correlated with the RAND-36 Role functioning/ physical scale on day 1, and the MFIS Physical and Psychosocial subscales on days 1 and 8.
Known-groups validity was demonstrated by symptoms domain scores differing significantly between RMS patients and controls (Table 4) .
All symptoms and impacts subdomains of the FSIQ-RMS exceeded the threshold for internal consistency, with Cronbach's alpha on day 1 ranging from 0.869 to 0.949. All symptoms and impacts subdomains also exceeded the threshold for demonstrating testeretest reliability, with ICCs ranging from 0.917 to 0.946.
Attribution analysis
The differential item functioning analysis, which was performed on the symptoms domain, found greater impairment on 3 items in patients with RMS compared with controls, confirming significantly worse fatigue in RMS patients compared with non-RMS individuals.
In a regression model controlling for age, cognition, and level of depression, there was a significant 14-point difference in symptoms score (scale range 0 to 100) between RMS patients and controls (P < .0001), demonstrating that the fatigue-related symptoms were attributable to RMS.
Stage 5: Real-World Study
Of 1597 MS patients for whom data were gathered in 2012, 154 completed the FSIQ-RMS symptoms measure and met the eligibility criteria for analysis. Results confirmed that the FSIQ-RMS symptoms domain items met the unidimensionality and local 
Stage 6: eDiary Migration and Usability Study
Data were analyzed for a total of 10 participants from 2 US sites who were interviewed in January 2015. On the device-usability questionnaire, all participants reported that it was easy or very easy to learn, use, navigate, read, and see the response choices of the eDiary.
In interviews, 7 participants (70%) spontaneously reported preferring the eDiary to the paper format, based on better ease of use (n ¼ 4), less information per page (n ¼ 2), being quicker and simpler to use (n ¼ 3), not having to write (n ¼ 1), and providing better flow (n ¼ 1). Participants generally interpreted the questionnaire the same way on the 2 platforms.
In the cognitive interviews, participants confirmed that the symptoms and impacts listed on the FSIQ-RMS were relevant to their experience with RMS. Participants generally reported understanding the meaning of the questions, instructions, and response options, though 2 participants mentioned confusion about the meaning of "at rest" in 1 question. After stage 6, examples were added to this question: "eg, reading a book, watching TV."
Discussion
Because fatigue is the most frequent symptom of MS and has a severe impact on patients' health-related quality of life, accurate measurement of fatigue is important in devising the best treatment strategies for each patient. 44 The final FSIQ-RMS is a valid and reliable PRO instrument that has demonstrated content and measurement validity for fatigue-related symptom and impact items. The multistage development and psychometric validation program established that the new questionnaire measures important aspects of fatigue symptoms attributable to relapsing forms of MS and the impacts resulting from these symptoms. Development and validation of the FSIQ-RMS were designed from the outset to be rigorous with respect to current requirements for PRO instrument development. Recently, other PRO instruments for assessing fatigue in patients with MS have been developed following different approaches; for example, the Neurological Fatigue Index (NFI-MS) comprises a 10-item summary scale, and scales measuring the physical and cognitive aspects of fatigue. 19 In contrast to the FSIQ-RMS, the NFI-MS is based on a fatigue-symptom framework. 45 Although the FSIQ-RMS has several strengths, including rigorous development following the FDA PRO guidance, 12 incorporation of the input of RMS patients, and psychometric validation performed in a stand-alone study that included controls to confirm attribution of symptoms to RMS, the instrument development also has limitations. Because of the mild-to-moderate disease of most participants, the validity of the FSIQ-RMS in patients with more severe disease (ie, those with EDSS >5.5) would have to be established in future research. As the instrument has not been assessed in MS subtypes other than RRMS, PRMS, and RSPMS, it cannot be assumed to be applicable to patients with different disease subtypes.
In conclusion, qualitative research and psychometric validation analyses indicate that the FSIQ-RMS is fit for purpose for measuring fatigue symptoms and impacts as a clinical study endpoint in RMS trials. Results of the migration and usability study confirmed the conceptual equivalence of the FSIQ-RMS eDiary to the paper version and its appropriateness for use with RMS patients. Responsiveness and meaningful change, as well as variability by language version and demographic subgroups (eg, sex, country), of the final FSIQ-RMS eDiary will be analyzed in 2 international phase 3 trials of ponesimod: OPTIMUM (ponesimod vs teriflunomide in patients with active RMS; NCT02425644) and POINT (add-on ponesimod to dimethyl-fumarate in patients with active RMS despite treatment with dimethyl-fumarate; NCT02907177). First results, coming from the OPTIMUM trial, are anticipated in 2019.
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